Definition of a fluorescence in-situ hybridization score identifies high-and low-level FGFR1 amplification types in squamous cell lung cancer

Modern Pathology

Volumn 25, Issue 11, 2012, Pages 1473-1480

  Schildhaus, Hans Ulrich ^a   Heukamp, Lukas C ^a   Merkelbach Bruse, Sabine ^a   Riesner, Katharina ^a   Schmitz, Katja ^a   Binot, Elke ^a   Paggen, Ellen ^a   Albus, Kerstin ^a   Schulte, Wolfgang ^b   Ko, Yon Dschun ^c   Schlesinger, Andreas ^d   Ansén, Sascha ^e   Engel Riedel, Walburga ^f   Brockmann, Michael ^f   Serke, Monika ^g   Gerigk, Ulrich ^b   Huss, Sebastian ^a   Göke, Friederike ^h   Perner, Sven ^h   Hekmat, Khosro ^e   Frank, Konrad F ^e   Reiser, Marcel ⁱ   Schnell, Roland ^j   Bos, Marc ^e   Mattonet, Christian ^e   Sos, Martin ^e,k   Stoelben, Erich ^f   Wolf, Jürgen ^e   Zander, Thomas ^e   Buettner, Reinhard ^a   more..

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^b Malteser Krankenhaus Bonn/Rhein Sieg   (Germany)

^c Johanniter Krankenhaus   (Germany)

^d Evangelisches Krankenhaus Kalk   (Germany)

^e UNIVERSITY OF COLOGNE   (Germany)

^f Kliniken der Stadt Koln GmbH   (Germany)

^g LUNGENKLINIK HEMER   (Germany)

^h UNIVERSITY HOSPITAL BONN   (Germany)

ⁱ PIOH Praxis Internistische Onkologie   (Germany)

^j Praxis Internistischer Onkologie und Hämatologie Frechen   (Germany)

^k UNIVERSITY OF CALIFORNIA   (United States)

more..

Author keywords

FGFR1; FISH; lung cancer; squamous cell; targeted therapy

Indexed keywords

FIBROBLAST GROWTH FACTOR RECEPTOR 1;

ARTICLE; CANCER CELL; CELL NUCLEUS; CENTROMERE; CONTROLLED STUDY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE CLUSTER; GENE DOSAGE; GENE FREQUENCY; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; LUNG ADENOCARCINOMA; LUNG CANCER; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MOLECULAR DIAGNOSIS; PREVALENCE; PRIORITY JOURNAL; SCORING SYSTEM; SIGNAL TRANSDUCTION;

ADENOCARCINOMA; CARCINOMA, SQUAMOUS CELL; FIXATIVES; FORMALDEHYDE; GENE AMPLIFICATION; GENE DOSAGE; GENETIC PREDISPOSITION TO DISEASE; GERMANY; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; LUNG NEOPLASMS; PARAFFIN EMBEDDING; PHENOTYPE; PREDICTIVE VALUE OF TESTS; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 1; REPRODUCIBILITY OF RESULTS; TISSUE FIXATION;

EID: 84868456197     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2012.102     Document Type: Article

References (23)

1. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361:947-957.
2. Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-smallcell lung cancer. Nature 2007;448:561-566. (Pubitemid 47206930)
3. Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010;363:1693-1703.
4. Shaw AT, Yeap BY, Solomon BJ, et al. Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. Lancet Oncol 2011;12:1004-1012.
5. Khuder SA. Effect of cigarette smoking on major histological types of lung cancer: a meta-analysis. Lung Cancer 2001;31:139-148. (Pubitemid 32107010)
6. Weiss J, Sos ML, Seidel D, et al. Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. Sci Transl Med 2010;2:62ra93.
7. Eswarakumar VP, Lax I, Schlessinger J. Cellular signaling by fibroblast growth factor receptors. Cytokine Growth Factor Rev 2005;16:139-149. (Pubitemid 40616112)
8. Grose R, Dickson C. Fibroblast growth factor signaling in tumorigenesis. Cytokine Growth Factor Rev 2005;16:179-186. (Pubitemid 40616115)
9. Mohammadi M, Olsen SK, Ibrahimi OA. Structural basis for fibroblast growth factor receptor activation. Cytokine Growth Factor Rev 2005;16:107-137. (Pubitemid 40616111)
10. Koziczak M, Holbro T, Hynes NE. Blocking of FGFR signaling inhibits breast cancer cell proliferation through downregulation of D-type cyclins. Oncogene 2004;23:3501-3508. (Pubitemid 38658416)
11. Cavallaro U, Christofori G. Cell adhesion and signalling by cadherins and Ig-CAMs in cancer. Nature Rev Cancer 2004;4:118-132. (Pubitemid 38198740)
12. Suyama K, Shapiro I, Guttman M, et al. A signaling pathway leading to metastasis is controlled by N-cadherin and the FGF receptor. Cancer Cell 2002;2:301-314. (Pubitemid 41043964)
13. Bass AJ, Watanabe H, Mermel CH, et al. SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas. Nat Genet 2009;41:1238-1242.
14. Zhao X, Weir BA, LaFramboise T, et al. Homozygous deletions and chromosome amplifications in human lung carcinomas revealed by single nucleotide polymorphism array analysis. Cancer Res 2005;65: 5561-5570. (Pubitemid 40911156)
15. Dutt A, Ramos AH, Hammerman PS, et al. Inhibitorsensitive FGFR1 amplification in human non-small cell lung cancer. PLoS One 2011;6:e20351.
16. Turner N, Grose R. Fibroblast growth factor signalling: from development to cancer. Nat Rev Cancer 2010;10:116-129.
17. Turner N, Pearson A, Sharpe R, et al. FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer. Cancer Res 2010;70:2085-2094.
18. Reis-Filho JS, Simpson PT, Turner NC, et al. FGFR1 emerges as a potential therapeutic target for lobular breast carcinomas. Clin Cancer Res 2006;12:6652-6662. (Pubitemid 44876833)
19. Travis WD, Brambilla E, Muller-Hermelink HK, Harris CC, (eds) World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart. IARC Press: Lyon, 2004, pp 26-67.
20. Varella-Garcia M, Diebold J, Eberhard DA, et al. EGFR fluorescence in situ hybridisation assay: guidelines for application to non-small-cell lung cancer. J Clin Pathol 2009;62:970-977.
21. Freier K, Schwaenen C, Sticht C, et al. Recurrent FGFR1 amplification and high FGFR1 protein expression in oral squamous cell carcinoma (OSCC). Oral Oncol 2007;43:60-66. (Pubitemid 46162249)
22. Elbauomy Elsheikh S, Green AR, Lambros MB, et al. FGFR1 amplification in breast carcinomas: a chromogenic in situ hybridisation analysis. Breast Cancer Res 2007;9:R23.
23. Wolf J, LoRusso P, Camidge R, et al. A phase I dose escalation study of NVP-BGJ398, a selective pan FGFR inhibitor in genetically preselected advanced solid tumors Abstract LB-122 AACR Annual Meeting. Chicago 2012.